FLOVENT HFA
ICS MDI
Fluticasone propionate · GlaxoSmithKline
Active Medication & Mechanism
- Fluticasone propionate ICS44 mcg, 110 mcg, or 220 mcg per actuation
Synthetic corticosteroid with potent anti-inflammatory activity. Reduces airway inflammation by suppressing inflammatory cell recruitment and cytokine production.
FDA-Approved Dosing by Indication
// approval varies by strength + age Asthma
3/4 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| 44 mcg | Patients ≥4 years | 2 inhalations twice daily (~12 hours apart) Starting dose for patients previously on bronchodilators alone. | 176 mcg | FDA Approved |
| 110 mcg | Patients ≥12 years | 2 inhalations twice daily For patients previously on ICS. Recommended starting dose for patients ≥12. | 440 mcg | FDA Approved |
| 220 mcg | Patients ≥12 years | 2 inhalations twice daily Maximum dose for patients previously on oral corticosteroids. | 880 mcg | FDA Approved |
| Any strength | Acute bronchospasm | — | — | Not Approved Not a bronchodilator. Not for acute bronchospasm. Use a SABA. |
Acute Use
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | Acute bronchospasm / rescue | — | — | Not Approved Not for acute relief. Use a SABA. |